BPC-157: Three Decades of Animal Work, a Thin Human File

The short version

BPC-157 stands for Body Protection Compound 157. It is a synthetic peptide, fifteen amino acids long, copied from part of a protective protein found in human stomach juice. In animal studies — overwhelmingly rats — it appears to speed up healing in many tissues: tendons, the gut lining, muscle, and nerve ^[5][6]. The explanation researchers give most consistently is that it helps the body grow new blood vessels into an injury site, which brings the oxygen and nutrients that repair requires ^[4].

Here is the honest part. Almost all of this evidence comes from animals. As of 2025 reviews, only three small human pilot studies exist, and there are no large, rigorous controlled trials ^[2]. BPC-157 is not an approved drug anywhere, it is banned in sport, and common online claims about weight loss, muscle building, or testosterone increases are not supported by published evidence ^[2]. This page summarizes what was studied — it is not advice, and no human dose is listed here.

What it is

BPC-157 is a stable gastric pentadecapeptide — "pentadecapeptide" means a chain of fifteen amino acids; "stable gastric" signals that the sequence is drawn from a cytoprotective (cell-protecting) protein in gastric juice and resists breakdown in the stomach environment. Its amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, and it is catalogued under research designations including PL 14736, PLD-116, PL-10, and Bepecin. It is a synthetic compound, not something extracted from a natural source, and not an approved drug anywhere in the world.

How it works

The best-characterized mechanism is angiogenesis — the formation of new blood vessels. In a 2017 study spanning a chick-membrane model, rat hindlimb ischemia, and human endothelial cells, BPC-157 increased expression of a key vessel-growth receptor called VEGFR2 and promoted its internalization, switching on the downstream VEGFR2-Akt-eNOS pathway; blocking that internalization blocked the effect ^[4]. In plain language: it appears to make blood-vessel cells more responsive to the body's own "grow new vessels" signal, and it accelerated blood-flow recovery in a blocked-circulation muscle model in the same study ^[4].

Beyond vessels, BPC-157 is described as a brain-gut-axis mediator that modulates serotonin and dopamine systems and engages cell-migration pathways including FAK-paxillin, Egr-1/NAB2, and JAK-2 signaling ^[7]. Separate reports describe sensitization of the growth-hormone receptor in tendon fibroblasts. The picture is of a peptide that nudges several repair-related signals at once rather than switching a single target.

What the research shows

Foundational cytoprotection. BPC-157's name traces to its gut origins. In Wistar rats it reduced gastric-ulcer area and accelerated ulcer healing — intramuscular delivery outperformed intragastric — with ulcer-formation inhibition ratios of roughly 46-66% at the higher doses tested ^[5].

Tendon healing. In a fully transected rat Achilles tendon, BPC-157 accelerated healing across biomechanical, functional, microscopic and macroscopic measures; it also stimulated tendocyte (tendon-cell) outgrowth in culture, with better collagen organization and restored tendon integrity versus untreated controls ^[6].

Pharmacokinetics. The first formal PK/ADME study, in rats and beagle dogs, found linear pharmacokinetics, a very short elimination half-life (under 30 minutes), modest intramuscular bioavailability (roughly 14-19% in rats, 45-51% in dogs), and rapid breakdown into small peptide fragments that re-enter normal amino-acid metabolism ^[3]. A short half-life means the intact peptide does not linger long in the bloodstream.

Human evidence. It is genuinely sparse. A 2025 first-in-human intravenous safety pilot gave BPC-157 up to 20 mg to two healthy adults; it was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[1]. That is encouraging — and it is two people in a safety pilot, not an efficacy study. A 2025 narrative review concludes that only three pilot studies have examined BPC-157 in humans, rigorous large-scale trials are lacking, and the peptide should be treated as investigational ^[2].

Reported effects, cautions & safety

The safety picture within the tiny human dataset and the animal work is reassuring as far as it goes — but "as far as it goes" is the key phrase. The absence of long-term, large-sample human safety data means the full safety profile is genuinely unknown ^[2].

Several cautions follow directly from the literature:

• Overwhelmingly preclinical. Most evidence comes from rodents, and a large share of foundational work originates from a single research group — newer authors explicitly flag independent-replication questions ^[2].
• Unregulated supply. BPC-157 is not an approved drug anywhere and is widely distributed through non-regulated channels, so product identity, purity and actual dose are unverifiable outside formal studies.
• Banned in sport. It is prohibited at all times by WADA under the S0 (non-approved substances) category — a direct concern for competitive athletes.
• Unsupported claims. Common online claims such as weight loss, muscle building, or testosterone increases are not supported by the published evidence and should be treated skeptically.

No community-anecdote reports are compiled in this site's source material for BPC-157 as a single compound; the cautions above are drawn from the cited literature only.

Where it fits in recovery research

Among the six compounds on this site, BPC-157 is the lead and the most broadly studied — but breadth is not depth. Its animal record spans tendon, gut, muscle and nerve, unified by an angiogenesis story, while its human file remains three small pilots ^[2]. Read alongside TB-500, which approaches repair through cell migration and actin biology, and GHK-Cu, which carries the strongest human (topical) data, BPC-157 illustrates the central tension of this whole field: a coherent, decades-deep preclinical signal that has barely crossed into controlled human work. The compare page shows how all six line up.